Innovations in Lymphoma Treatment and the Growing Impact of Bispecific Antibodies

Program Description

Bispecific antibodies (BsAbs) are revolutionizing the treatment of relapsed or refractory (R/R) follicular lymphoma and diffuse large B-cell lymphoma by offering effective, off-the-shelf T-cell–redirecting therapies with manageable safety profiles. Pharmacists are integral in guiding treatment selection, supporting transitions of care, and contributing to the development of protocols and educational initiatives that ensure consistent, high-quality care across various institutions. This article provides a comprehensive review of the latest clinical data supporting BsAbs in lymphoma, their advantages over CAR T-cell therapies, and their integration into earlier lines of therapy and combination regimens. Best practices for managing unique toxicities, such as cytokine release syndrome, and coordinating care across inpatient and outpatient settings will also be discussed to equip oncology pharmacists and managed care professionals to optimize BsAb access, enhance patient safety, and improve cost-effectiveness.

Target Audience: Managed care pharmacists and oncology pharmacists

Type of Activity: Application
Release date: August 6, 2025
Expiration date: August 6, 2026
Learner level: Foundational, Intermediate
Time to complete activity: 2.0 hours
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Examine the recent clinical data for new and emerging indications that incorporate bispecific antibodies (BsAbs) in the treatment of relapsed/refractory follicular lymphoma and diffuse large B-cell lymphoma.
• Explore the best practices for supporting transitions of care and ensuring safe and effective use of BsAbs in the treatment of lymphoma.
• Investigate innovative approaches in managed care to address logistical and operational hurdles, enabling broader access to BsAbs and improved clinical outcomes for patients. 

Pharmacy Times Continuing Education^™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 2.0 contact hours (0.20 CEU) under the ACPE universal activity number 0290-0000-25-235-H01-P. The activity is available for CE credit through August 7, 2026.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, view the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Sarah Profitt, PharmD, BCOP, has the following relevant financial relationships with commercial interests to disclose:

Consultant: Genentech, Inc
Advisory Board: Rigel Pharmaceuticals, Eli Lilly & Co, Blueprint Medicines

The following contributors have no relevant financial relationships with commercial interests to disclose:

Medical Writing and Editorial Support

Brianna Winters, MA

Pharmacy Times Continuing Education^™ Planning Staff—Jim Palatine, RPh, MBA; Daphne Davis, PharmD, BCOP; Crissy Wilson; Susan Pordon; and Chloe Taccetta have no relevant financial relationships with commercial interests to disclose.

At least one anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms